CR9627A - Cyanopyrrole-sulfonamide progesterone receptor modulators and uses thereof - Google Patents

Cyanopyrrole-sulfonamide progesterone receptor modulators and uses thereof

Info

Publication number
CR9627A
CR9627A CR9627A CR9627A CR9627A CR 9627 A CR9627 A CR 9627A CR 9627 A CR9627 A CR 9627A CR 9627 A CR9627 A CR 9627A CR 9627 A CR9627 A CR 9627A
Authority
CR
Costa Rica
Prior art keywords
receptor modulators
progesterone receptor
cyanopyrrole
sulfonamide
formula
Prior art date
Application number
CR9627A
Other languages
English (en)
Inventor
Casey Mccomas
Andrew Fensome
Edward MELENSKI
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CR9627A publication Critical patent/CR9627A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Se describen los moduladores del receptor de la progesterona de formula (I), o una sal farmaceuticamente aceptable del mismo, Formula (I); en donde R1, R2, R3, R4, R5, R6 y R7 son como define en la presente, son utiles para la anticoncepcion y terapia de reemplazo hormonal; tambien se proporcionan productos que contienen estos compuestos.
CR9627A 2005-07-29 2007-12-20 Cyanopyrrole-sulfonamide progesterone receptor modulators and uses thereof CR9627A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70400905P 2005-07-29 2005-07-29

Publications (1)

Publication Number Publication Date
CR9627A true CR9627A (es) 2008-03-06

Family

ID=37309001

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9627A CR9627A (es) 2005-07-29 2007-12-20 Cyanopyrrole-sulfonamide progesterone receptor modulators and uses thereof

Country Status (22)

Country Link
US (1) US7291643B2 (es)
EP (1) EP1910285A1 (es)
JP (1) JP5185114B2 (es)
KR (1) KR20080031915A (es)
CN (1) CN101233104A (es)
AR (1) AR056005A1 (es)
AU (1) AU2006275833B2 (es)
BR (1) BRPI0614412A2 (es)
CA (1) CA2612977A1 (es)
CR (1) CR9627A (es)
EC (1) ECSP088147A (es)
GT (1) GT200600336A (es)
HN (1) HN2008000135A (es)
IL (1) IL188314A (es)
MX (1) MX2008001338A (es)
NO (1) NO20076683L (es)
PE (1) PE20070404A1 (es)
RU (1) RU2007148077A (es)
SA (1) SA06270246B1 (es)
TW (1) TW200734302A (es)
UA (1) UA92500C2 (es)
WO (1) WO2007016212A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20070182A1 (es) * 2005-07-29 2007-03-06 Wyeth Corp Derivados cianopirrol-fenil amida como moduladores del receptor de progesterona
PE20070341A1 (es) * 2005-07-29 2007-04-13 Wyeth Corp Derivados de pirrol como moduladores del receptor de progesterona
TW200848019A (en) * 2007-03-06 2008-12-16 Wyeth Corp Aryl sulfonamides useful for modulation of the progesterone receptor
TW200848021A (en) * 2007-03-06 2008-12-16 Wyeth Corp Sulfonylated heterocycles useful for modulation of the progesterone receptor
EA201070715A1 (ru) * 2007-12-20 2011-02-28 Тева Вимен'С Хелс, Инк. Режимы дозирования, фармацевтические композиции и упаковки для экстренной контрацепции
WO2014071298A1 (en) 2012-11-05 2014-05-08 Nant Holdings Ip, Llc Cyclic sulfonamide containing derivatives as inhibitors of hedgehog signaling pathway

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680413A (en) * 1986-01-17 1987-07-14 Nippon Soda Co., Ltd. Process for the production of 3-phenyl-4-cyanopyrroles
US5455263A (en) 1987-07-29 1995-10-03 American Cyanamid Company Methods for the control and the protection of warm-blooded animals against infestation and infection by helminths, acarids and arthropod endo- and ectoparasites
EP0339342A1 (de) 1988-04-23 1989-11-02 Bayer Ag N-Substituierte N-Amino-pyrrole
GB8903592D0 (en) 1989-02-16 1989-04-05 Boots Co Plc Therapeutic agents
DE4036645A1 (de) 1990-11-16 1992-05-21 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, deren enthaltende mittel und deren verwendung
JP2699024B2 (ja) 1990-11-22 1998-01-19 富士写真フイルム株式会社 新規な色素形成カプラーおよび該カプラーを含有するハロゲン化銀カラー写真感光材料
US5236925A (en) 1991-10-24 1993-08-17 American Home Products Corporation Fused pyrimidines as angiotensin II antagonists
US5187168A (en) 1991-10-24 1993-02-16 American Home Products Corporation Substituted quinazolines as angiotensin II antagonists
WO1994017059A1 (fr) 1993-01-29 1994-08-04 Nippon Soda Co., Ltd. Derive heterocyclique
BR9608502A (pt) 1995-06-07 1999-07-06 Nippon Shinyaku Co Ltd Derivado da pirrola e composição medicinal
US6013421A (en) 1996-07-19 2000-01-11 Fuji Photo Film Co., Ltd. Silver halide photographic light-sensitive material and image-forming method
US20010007867A1 (en) 1999-12-13 2001-07-12 Yuhpyng L. Chen Substituted 6,5-hetero-bicyclic derivatives
US6407101B1 (en) * 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
ES2251582T3 (es) 2001-03-09 2006-05-01 Pfizer Products Inc. Compuestos antiinflamatorios de bencimidazol.
DE60210755T2 (de) 2001-03-09 2006-11-16 Pfizer Products Inc., Groton Triazolopyridine als entzündungshemmende mittel
ATE304009T1 (de) 2001-04-04 2005-09-15 Pfizer Prod Inc Neue benzotriazole mit entzündungshemmender wirkung
EP1575919A1 (en) 2002-11-11 2005-09-21 Bayer HealthCare AG Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist
EP1594438B1 (fr) 2003-02-12 2013-07-17 L'Oréal Utilisation d'un inhibiteur de 15-hydroxy prostaglandine déshydrogénase pour favoriser la pigmentation de la peau ou des phanères
ATE396189T1 (de) 2004-04-27 2008-06-15 Wyeth Corp Cyanopyrrolhaltige cyclische carbamat- und thiocarbamatbiaryle und verfahren zu deren herstellung
GT200500183A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
GT200500185A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos

Also Published As

Publication number Publication date
MX2008001338A (es) 2008-03-25
CN101233104A (zh) 2008-07-30
UA92500C2 (ru) 2010-11-10
US7291643B2 (en) 2007-11-06
KR20080031915A (ko) 2008-04-11
SA06270246B1 (ar) 2010-11-22
AR056005A1 (es) 2007-09-12
GT200600336A (es) 2007-05-28
BRPI0614412A2 (pt) 2016-11-22
RU2007148077A (ru) 2009-09-10
WO2007016212A1 (en) 2007-02-08
JP2009502947A (ja) 2009-01-29
ECSP088147A (es) 2008-02-20
NO20076683L (no) 2008-02-04
US20070027126A1 (en) 2007-02-01
AU2006275833A1 (en) 2007-02-08
PE20070404A1 (es) 2007-05-10
TW200734302A (en) 2007-09-16
IL188314A0 (en) 2008-04-13
JP5185114B2 (ja) 2013-04-17
CA2612977A1 (en) 2007-02-08
EP1910285A1 (en) 2008-04-16
IL188314A (en) 2012-09-24
HN2008000135A (es) 2010-08-19
AU2006275833B2 (en) 2012-04-26

Similar Documents

Publication Publication Date Title
ECSP088412A (es) Derivados de pirazina como moduladores de canal de sodio en el tratamiento del dolor
CL2008000669A1 (es) Compuestos derivados de tiazolidindionas n alquiladas, moduladores del receptor alfa relacionados con estrogenos; composicion farmaceutica; y su uso para tratar enfermedades relacionadas con los huesos, cancer, sindrome metabolicos, entre otras.
CL2011000835A1 (es) Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras.
CR9022A (es) Derivados de sulfonamida novedosos como moduladores de receptor de glucocorticoides para el tratamiento de enfermedades inflamatorias
CR9627A (es) Cyanopyrrole-sulfonamide progesterone receptor modulators and uses thereof
CY1119865T1 (el) Φαρμακευτικες συνθεσεις για την αντιμετωπιση της νοσου του παρκινσον
AR057060A1 (es) Composiciones de tanaproget que contienen etinil estradiol
AR065135A1 (es) Compuestos triciclicos, composicion que los comprende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por el receptor de glucocorticoides.
ECSP077323A (es) Nuevos derivados de sulfonamida como moduladores del receptor de glucocorticoides para el tratamiento de enfermedades inflamatorias
UY27436A1 (es) Compuestos químicos
ECSP066711A (es) Moduladores del receptor selectivo del estrogeno para el tratamiento de sintomas vasomotores
CL2011001658A1 (es) Compuestos derivados de sulfonamidas, moduladores de los canales de sodio; composición farmacéutica que los comprende; y su uso en el tratamiento del dolor.
AR064692A1 (es) Derivados de oxindol sustituido medicamentos que los comprenden y uso de los mismos
EA201170198A1 (ru) Фармацевтические композиции, содержащие лиганды рецептора дофамина
UY33075A (es) Derivados de ciclohexano y usos de los mismos
ECSP099425A (es) Derivados de amina y su uso en enfermedades mediadas por el adrenorecetor beta 2
UY29320A1 (es) 18-metil-19-nor-17-pregn-4-en-21, 17-carbolactonas, así como preparaciones farmacéuticas que las contienen
ECSP10010168A (es) Benzotiazolas como moduladores del receptor de ghrelina
AR054586A1 (es) Uso de moduladores del receptor de progesterona
UY29197A1 (es) Compuestos de n-sulfonilaminobencil-2-fenoxiacetamida sustituidos
CR9595A (es) Derivados de benzofurarona como moduladores no esteroides de receptores de progesterona
HN2009001441A (es) Compuestos de 2- aminopirimidina como potentes inhibidores de hsp-90
SV2011003896A (es) Pirrolidinas
GT200600335A (es) Moduladores del receptor de progesterona cianopirrol-fenil amida y usos de los mismos
AR119317A1 (es) Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)